Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Limited will announce its financial and operating results for the half-year ending December 31, 2024, on February 26, 2025. The results will be discussed in a webinar hosted by CEO Melinda McGrath and CFO Matthew Cordingley, offering stakeholders insights into the company’s performance and future outlook.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that perform a wide range of pathology tests for various clients including doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in the country and is committed to leveraging talented personnel, medical and scientific expertise, and innovative technologies to enhance patient care and decision-making.
YTD Price Performance: 9.01%
Average Trading Volume: 509,236
Technical Sentiment Consensus Rating: Sell
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.
